Hepatitis C New Drug Research And Liver Health
  • HCV News Of The Day
    • 2013/HCV Drugs News Digest
    • HCV Drugs: News Digest>
      • News Archive
      • Liver HCV : Specialty news digest
  • 2013 - Breaking Conference Reports/Hepatitis C
    • Breaking Conference Reports >
      • EASL 2012 Meeting Summary>
        • EASL Summary Of The 2011 March Meeting
      • AASLD- Nov 2011 Annual Meeting>
        • Conference Archive
  • Blog: New HCV Drug Updates
  • HCV FAQ
  • HCV: Newly Diagnosed?
    • Challenges-issues in managing hepatitis C
    • Ask Me A Question About Hepatitis C
  • What to do with a positive hepatitis C test
  • 2013-HCV Abstract Corner
    • HCV Abstract Corner>
      • Archive; Abstract Corner
  • 2013-Hepatitis C Full Text Articles
    • Hepatitis C Treatment Complete Studies 2012>
      • Potential new method to block the lifecycle of the Hepatitis C virus
      • Hepatitis C Treatment Complete Studies 2011
  • 2013/HCV Multimedia Videos Podcasts
    • Multimedia/Videos-Podcasts>
      • Watch How Hepatitis C Protease Inhibitors Work>
        • Multimedia; Archives Videos and Podcasts
  • 2013 Stem Cell News and Research
    • Liver-2012 Stem Cell Updates
    • Liver: 2011 Stem Cell Updates
    • What Are Stem Cells?>
      • Future applications of human stem cells
  • Recommended; Stem Cell Blogs
  • Understanding Hepatitis C
  • Natural History Of HCV
    • A 20-year cohort study on the natural history of untreated HCV infection
  • Hepatitis C Disease Progression
    • NIH scientists identify likely predictors of hepatitis C severity
    • HCV Epidemiology, Diagnosis and Disease Progression
    • Hepatitis C may increase deaths from both liver-related and other diseases>
      • Mortality in advanced HCV /long-term peginterferon
    • Host Factors on Management of HCV
  • Transmission
    • How Soon To Initiate HCV Therapy After Transmission
    • Does the Hepatitis C virus survive in dried blood ?
    • Viral Load Tied to Vertical Transmission of Hepatitis C
    • Hey Can I Get Hep C From......
    • HCV infections transmitted via a clinical setting
    • What Should I Do If I Get A Needlestick
  • How are the different types of hepatitis transmitted
    • New challenges in viral hepatitis
    • Hepatitis A virus infection in high-risk subjects
  • Your Liver Functions
  • Liver Function Tests
    • HCV-Persistently Normal (ALT) Alanine Aminotransferase Levels
    • Hey, I have a question about hcv tests and my liver
    • ALT used to separate those infected with HCV from those at low risk of liver disease
  • Lab Reports
  • HCV Viral Load Test
  • Liver Biopsy/Noninvasive Tests
    • Is there still a role for liver biopsy in managing hepatitis C virus infections?
    • Overview of Liver Biopsy Procedure
    • Three Algorithms of Non-invasive Markers of Fibrosis in Chronic Hepatitis C
    • FibroScan comparison to liver fibrosis biomarkers
  • Chronic HCV Symptoms
    • Fatigue and HCV
    • Sleep Disturbance in Chronic HCV
    • Skin Rash/Hepatitis C
    • Liver Disease: Bone Loss "It Ain't Like Menopause!"
  • HCV Neuropsychiatric symptoms-“brain fog”
    • HCV-Related Nervous System Disorders
    • Hepatitis C Virus and the Brain
    • Liver-induced inflammation hurts the brain
    • The Brain on Fire: Inflammation and Depression
  • Conditions Outside The Liver
    • Prevalence of fibromyalgia among patients with chronic hepatitis C
    • Lichen Planus and The Hepatitis C Virus
    • Dermatologic Disorders and Liver Disease
  • Chronic hepatitis C: Treat or wait?
    • Preparing For Treatment>
      • Starting Hepatitis C Treatment: Tips and Information 2011
      • Adherence To HCV Treatment-Review
      • Treating Hepatitis C; What can you do to increase your chance for SVR?
  • Hepatitis C advanced fibrosis: Treat or Wait
  • Approved Treatments for Hepatitis C
    • Adults:Treating Hepatitis C
    • Interferons and hepatitis C virus
  • HCV Treatment Failure Can Still Mean Less Liver Inflammation
  • Protease inhibitors geno-1:New standard of care
    • Treating HCV Genotype 1 In The Real World
    • 2012 - Direct acting antivirals for the treatment of chronic hepatitis C
    • HCV:End of the Beginning-Possibly-Beginning of the End
    • Patients’ Expectations About New HCV Direct-Acting Antivirals Often Unrealistic
    • What Are NS5A inhibitors ?
    • Hepatitis C Treatment Nonresponders
    • New 2011 AASLD guidelines for treating HCV
    • Treating New and Old Therapies>
      • High-grade liver inflammation may predict treatment response
  • HCV Resistance To New And Experimental Drugs
    • Understanding Resistance in Chronic HCV Infection
  • 2012 Future Prospects-Treatment of HCV
    • Advances in the treatment of hepatitis C virus infection.
  • Boceprevir & Telaprevir
    • FDA Telaprevir/Boceprevir Transcript
    • Pocket Guide Telaprevir/Boceprevir
    • Quick Facts- Direct-acting antivirals Telaprevir/Boceprevir
    • Telaprevir Or Boceprevir: What Is My Chance For A Cure?
  • 2013 News/Incivek (Telaprevir)
    • News/Telaprevir>
      • Telaprevir-IFN/ribavirin Hints at Response
      • Telaprevir FDA Approval>
        • Help-How Do I Take Incivek-telaprevir ?
        • Quick Study Of Telaprevir
        • Cost Of Treating With Telaprevir
  • 2013 News/Victrelis (Boceprevir)
    • News/ Boceprevir>
      • VICTRELIS-Boceprevir: Prescribing-Medication Guide
      • 2011;Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
      • 2011-Boceprevir for Untreated Chronic HCV Genotype 1 Infection
  • Side Effects-Interferon Free Therapies
  • Drug-Drug Interactions In Triple-Therapy
  • 2013/HCV Triple-therapy Side Effects
    • Boceprevir,Telaprevir Less Side Effects?>
      • 2013-HCV therapy geno 1: management of side-effects
      • Dry Mouth and Treatment >
        • Dry Mouth (Xerostomia)
      • Important updates to PegIntron labeling
      • Peginterferon alfa-2a Drug Interactions
      • HCV Treatment: Peginterferon and Ribavirin Side Effects
  • Genotypes/Treatment
    • Treatment Duration in Hepatitis C Virus Genotype 2/3-infected Patients
    • Impact of IL28B on Liver Histopathology in HCV Genotype 2/3
    • Genotype 3/HCV Treatment
    • HCV-Genotype 5 or 6
    • Hepatitis C-Genotype 4>
      • How to optimize HCV therapy in genotype 4 patients
      • Geno 4-Pioglitazone Decreases HCV Viral Load
    • Telaprevir/Boceprevir *genotype 1,2,3
    • (HCV) genotypes in the severity of liver disease
  • What Is The IL28B gene ?
    • Hepatitis C Test:Likelihood of achieving SVR>
      • IL28B and HCV immune responses
  • Index-Current Hepatitis C Drugs In Development
  • 2013-Interferon Free Combinations
    • Interferon-free combinations
    • 2013-Interferon free therapy w-direct acting antivirals for HCV
  • 2013 Sofosbuvir (GS-7977)
    • GS-7977-Formally PSI-7977 >
      • PSI-7977 peg/riba Geno 2/3 PROTON Trial
  • Sofosbuvir(GS7977)/Simeprevir(TMC435)
    • Interferon-Free Combo PSI-7977-TMC435
  • Sofosbuvir (GS-7977)/Ledipasvir (GS-5885)
  • GS-5885, an NS5A Inhibitor
  • ABT-450/r, ABT-267, ABT-333
  • Faldaprevir (BI 201335) and BI 207127 Interferon-Free
    • NS3/4A protease inhibitor BI201335
  • Miravirsen First MicroRNA-Targeted Drug
  • BMS-790052 (Daclatasvir)
  • Daclatasvir/VX135
  • ALS-2200 (VX-135)
  • BMS-790052/BMS-650032 Interferon-sparing
  • (TMC435) Simeprevir
  • TMC435 monotherapy in HCV genotypes 2-6
  • Simeprevir (TMC435) and TMC647055
  • Simeprevir,TMC647055 and IDX719
  • TMC435-daclatasvir-BMS-790052
  • Danoprevir-RG7227 direct-acting antiviral
  • Mericitabine- Polymerase Nuc
  • Sovaprevir (Formerly ACH-1625)
  • ACH-3102 NS5A inhibitor
  • INCIVEK, VX-222/Ribavirin
  • MK-5172 protease inhibitor
  • HCV/New Drug Pipeline
  • 2013/Hepatitis C Clinical Trials
    • Clinical Trials>
      • Learning About Clinical Trials
      • Boceprevir and Telaprevir Trials>
        • Telaprevir REALIZE STUDY
  • HCV Trials/Discontinued Or On Hold
    • Idenix IDX184-Hepatitis C drug
    • TMC435-BMS-986094-formerly INX-189
  • Women's Health; Treating Hepatitis C
    • Early Menopause and Response to HCV Treatment
  • Hepatitis C in Pregnancy
  • Treating Hepatitis C In Children
    • 2012 Hepatitis C infection in children
    • Autoimmunity/Extrahepatic Manifestations in HCV Treatment-Naïve Children
    • Study-long-term safety/durability of virologic response in paediatric patients who were previously treated w-interferon alfa-2b plus ribavirin for 48 weeks
  • Liver Disease in Elderly Patients
  • Dental considerations in patients with liver disease
    • HCV: Dental management-Diagnosis of extrahepatic manifestations>
      • Dental problems delaying the initiation of interferon
  • Fibrosis
    • Is there a natural way to improve liver fibrosis ?
  • 2013 News/Fibrosis
    • News: Fibrosis
  • Cirrhosis
    • What Is Cirrhosis ?
    • Advanced Liver Disease: What Every HCV Treater Should Know
    • The Patient With Cirrhosis: Don't Miss This
    • Hey, I have a question about cirrhosis
    • Physical Findings Suggestive Of Cirrhosis/Photos
    • Staging Cirrhosis>
      • When the Spleen Gets Tough, the Varices Get Going
    • Management Cirrhosis: How Are We Doing?
    • Cirrhosis Regression
    • Cirrhosis ; Surgery in the Patient with Liver Disease
    • Hepatic Encephalopathy>
      • Varices
      • Ascites
      • Management of ascites
  • 2013 News/Cirrhosis
    • News: Cirrhosis>
      • GI Bleeds: Withholding Transfusions Boosts Survival
  • Liver Transplant
    • New HCV Drugs:Expected Risks-Challenges in Liver Transplant
    • Prevention of hepatitis C recurrence after liver transplantation>
      • Effects of Telaprevir on Cyclosporine and Tacrolimus Pharmacokinetics Make Utility in Post-OLT Setting Uncertain
      • HCV Treatment After Liver Transplant
      • Antivirals Ineffective Against HCV After LT
  • 2013 News/Transplant
    • Liver Transplant News
  • Hepatocellular Carcinoma
    • Audio:Liver Cancer
    • Radioembolisation (RE),Selective Internal Radiation Therapy (SIRT)
    • Diagnosis (markers) of early hepatocellular carcinoma
    • Intrahepatic cholangiocarcinoma
    • Treatment TheraSphere/HCC/primary liver cancer
    • Liver Cancer : Microwave Ablation (MWA)
    • Pain May Predict Liver Cancer Prognosis
    • What Is the Indication for Sorafenib in Hepatocellular Carcinoma?
    • Liver Cysts and Tumors"Two Totally Different Concepts"
    • Interactive map of cancer mortality risk worldwide
  • 2013 News/Liver Cancer
    • Liver Cancer News and Updates
    • Vitamin E may lower liver cancer risk
  • Guidelines Nonalcoholic Fatty Liver Disease (NAFLD)
    • Fatty Liver And HCV>
      • Touching some firm ground in the epidemiology of NASH
      • Ultrasound/Liver Biopsy
      • Fatty Liver and Treatment
      • Liver fibrosis/Fatty Liver
  • 2013-Coffee and Liver Disease
  • Liver Regeneration
  • Liver Health
    • Choline: Great for the Liver
    • Medications for sleep in liver disease
    • The odds of gallbladder disease in Hepatitis C Patients
    • HCV & Gallbladder Disease:
    • Enlarged Spleen
    • HCV And Cardiovascular Risk
  • Nutrition-Herbs-Vitamins
    • Vitamin D and Treatment
    • Liver Disease - The Mediterranean Diet
    • Diet: Cirrhosis>
      • Low-Salt Diet-A Must in Cirrhosis
      • Diet for Liver Disease Low Sodium and More
      • Vitamin B12 supplements may help treat hepatitis
      • Nutrition in end-stage liver disease
      • Cirrhosis; Vitamin K Deficiencies
      • Vitamin D Levels In Cirrhosis
      • Vitamin D could de-stress Liver Disease Treatments
      • Drugs And Cirrhosis
      • Cancer and Berries
  • 2013-Silymarin for HCV infection
  • Milk Thistle
    • 2012-Milk Thistle No Help in Tough Hepatitis C Cases
    • Silymarin-Milk Thistle for NAFLD
    • Milk thistle"- Silibinin in hepatitis C related liver transplantation
    • Milk Thistle is coming to America
    • Caution! Herbs and Nutritional Supplements
  • HCV Drugs: Financial Support
  • HCV Filing For Social Security
  • Hepatitis C: A Rational Call To Arms
    • Hepatitis C; A Forced Legacy
    • Outsourcing:Globalization of the pharmaceutical industry>
      • Inspirational
  • Hepatitis C Links / Best On The Web
    • Chat and Message Boards
  • Whose Website Is This ?
  • Feedback/Contact Us
Fatty Liver/Treatment

Impact of Hepatic Steatosis on Natural History of Chronic HCV Infection:
./ 

Discussion // 

 Hepatic Steatosis (Fatty  Liver Disease) ,/ Steatosis = fatty changes .
./
Hepatic steatosis ( Fatty Liver ) is a recognized feature of Chronic Hepatitis C CHC

How Many Untreated Patients Were In The Study ? ,/

In this retrospective analysis of a cohort of 112 untreated patients, the prevalence of steatosis (Fatty Liver ) was 46% on index liver biopsy, which is comparable to the 50% prevalence reported in a large meta-analysis.[21] /

What Factors Parallel With Fatty Liver Disease ?
Genotype 3 /

 Several factors were found to correlate with steatosis on the first biopsy by univariate analysis including male sex, raised γGT and fibrosis, but only infection with HCV genotype 3 was identified as being independently associated on multivariate analysis. This observation is consistent with previous reports that have examined the relationship between hepatic steatosis and HCV genotype.[19,22–24] ./

Genotype 1 and other factors .

 The mechanisms responsible for steatosis appear to be dependent on HCV genotype; with metabolic features, e.g. obesity, diabetes mellitus and elevated body mass index, appearing to account for the increased levels of hepatic steatosis in genotype 1. /. In such cases, it is believed that insulin resistance plays a major role, leading to adipocyte lipolysis and an increase in circulating free fatty acids, which together with inhibition of hepatic lipid oxidation and export lead to triglyceride deposition in the liver.[8,9,25,26]

. Fatty Liver In Genotype 3 Is A Direct Action To The Virus /.

 In contrast, steatosis in patients with genotype 3 appears to occur as a direct action of the virus infection.[19,22] Furthermore, successful eradication of the virus using combination therapy with peginterferon and ribavirin, leads to a diminution of the extent of steatosis among patients infected with genotype 3 but not in those infected with other genotypes.[24,27]
/.
Fatty Liver And Progression Of LIver Fibrosis : The Controversy

./ The association between hepatic steatosis and progression of liver fibrosis is a source of controversy, as some studies have implicated steatosis as a factor in fibrosis progression,[16,19,27] whereas others have found no correlation.[28,29] Many studies have been criticized for using cross-sectional analysis to examine the relationship with steatosis and fibrosis, when neither the duration of steatosis nor duration of infection was well documented l Therefore, we performed a longitudinal study on 112 patients who had undergone two liver biopsies separated by an average of 4.17 years. Worsening of fibrosis occurred in 21% of patients and on univariate analysis several factors were found to correlate with an increase in fibrosis. . However, using multivariate linear regression analysis only the presence of steatosis on the first biopsy was independently associated with fibrosis progression both to significant fibrosis (Ishak F ≥ 3) and cirrhosis (Ishak F5–6). This finding confirms reports by other groups[16,19,27] and a recent meta-analysis[21] that steatosis is associated with fibrosis progression. The confidence intervals for steatosis and fibrosis progression were extremely broad. . This problem may have been compounded by the small numbers of patients in each steatosis and Ishak Fibrosis group. Steatosis groups were collapsed to a binary variable to allow a simple analysis to be performed to determine if it was associated with fibrosis progression. A further explanation accounting for differences in fibrosis stage between liver biopsies may be sampling error, indeed, the problems of sampling error from liver biopsy in CHC are well documented.[32] .

Progression of Fibrosis In Genotype 1 and 3
.

Although we found that HCV genotype 3 was associated with steatosis, we did not demonstrate an association between this and any other specific genotype and fibrosis progression. / However, this was not unexpected as other studies have presented conflicting evidence, some suggesting an association with genotype 3 and fibrosis progression,[20,31,33] whereas others support a role only for genotype 1.[21,27]
.
The mechanism by which steatosis may lead to worsening fibrosis is not understood. The factors implicated include the impact of oxidative stress, insulin resistance, and an increased susceptibility to apoptosis leading to worsening fibrosis[34] because of its associated with activation of hepatic stellate cells.[35] Evidence in favour of the latter mechanism comes from the observation that caspase activity, which regulates apoptosis,[36] correlates with steatosis activity and is increased in CHC.
.
Our study could be criticized because of the absence of data on quantitative HCV RNA levels and the patient's body mass index. However, these parameters have been extensively studied before and many authorities accept a correlation between genotype 3 HCV RNA level and steatosis,[19,22] and the greater impact of metabolic factors on the development of steatosis in patients with HCV genotype 1.[37–40] In the absence of body mass index data and information regarding insulin resistance, it was not possible to gain further insights into their contribution to steatosis in this study.

. Steatosis Diminishes as Fibrosis Worsens in Chronic Hepatitis C Virus

.
On the second biopsy, the number of patients with mild steatosis increased, whilst, the number of patients with moderate to severe steatosis decreased. , This is not unexpected because it has been observed previously that steatosis diminishes as fibrosis worsens in CHC[33] and in NAFLD.[41] ,

 Alcohol Consumption and Fibrosis Progression In Hepatic Steatosis

, Finally, the authors wanted to evaluate whether concurrent alcohol consumption would exacerbate hepatic steatosis and fibrosis progression. The relationship between chronic hepatitis C infection and alcohol leading to more severe disease is well described.[3] . However, in this study alcohol consumption was shown not to be associated with steatosis or fibrosis progression. This is likely to be because the numbers of patients documented as having high alcohol consumption were small, and also because of the relationship between CHC and steatosis makes it difficult to determine if the observed steatosis is related to alcohol consumption, viral or metabolic factors. . A further problem relates to the method used to assess alcohol consumption. Patients often under-estimate their alcohol consumption and more robust ways to accurately quantify alcohol consumption are needed.[42] Given the retrospective nature of data collection, this aspect of the study is prone to error.
. In addition, patients actively drinking were excluded from the final analysis, further complicating interpretation.
,
 Summary ,

In summary, this study of 112 patients, who had undergone two liver biopsies separated by an average of 4.17 years, demonstrated that the presence of steatosis on the first biopsy was independently associated with fibrosis progression on the second biopsy. . This finding indicates that, independent of baseline fibrosis stage, patients should be considered for anti-viral treatment if steatosis is present. , Furthermore, it is recognized that metabolic factors contribute to the development of steatosis, suggesting that their control may reduce the likelihood of fibrosis progression.,,,,,,,,,,, Continue reading .....,Summary and Introduction

Picture


Click Below For Complete Study, the above is only the :

Discussion .
Table Of Contents: .
Summary and Introduction
Patients and Methods

Results
Discussion

References . T. J. S. Cross; A. Quaglia; S. Hughes; D. Joshi; P. M. Harrison
Authors and Disclosures
Posted: 10/08/2009; J Viral Hepat. 2009;16(7):492-499. © 2009
Copyright 2010-2013 Hepatitis C New Drug Research And Liver Health